Charles River Laboratories International, Inc. (NYSE:CRL) Shares Sold by TD Waterhouse Canada Inc.

TD Waterhouse Canada Inc. decreased its stake in Charles River Laboratories International, Inc. (NYSE:CRL) by 21.5% in the 4th quarter, Holdings Channel reports. The firm owned 1,351 shares of the medical research company’s stock after selling 371 shares during the quarter. TD Waterhouse Canada Inc.’s holdings in Charles River Laboratories International were worth $249,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Virtu Financial LLC acquired a new stake in Charles River Laboratories International in the third quarter valued at $601,000. Wilmington Savings Fund Society FSB acquired a new stake in Charles River Laboratories International in the 3rd quarter valued at about $59,000. Tidal Investments LLC grew its stake in Charles River Laboratories International by 37.8% in the 3rd quarter. Tidal Investments LLC now owns 8,452 shares of the medical research company’s stock valued at $1,665,000 after acquiring an additional 2,319 shares during the last quarter. Lord Abbett & CO. LLC raised its position in Charles River Laboratories International by 5.8% during the third quarter. Lord Abbett & CO. LLC now owns 108,715 shares of the medical research company’s stock worth $21,413,000 after acquiring an additional 5,959 shares during the last quarter. Finally, Principal Financial Group Inc. lifted its holdings in shares of Charles River Laboratories International by 3.6% in the third quarter. Principal Financial Group Inc. now owns 60,501 shares of the medical research company’s stock valued at $11,917,000 after purchasing an additional 2,126 shares in the last quarter. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on the company. William Blair downgraded Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a research report on Wednesday, January 22nd. Mizuho cut their price target on Charles River Laboratories International from $175.00 to $155.00 and set a “neutral” rating for the company in a report on Wednesday, April 9th. The Goldman Sachs Group downgraded Charles River Laboratories International from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $190.00 to $170.00 in a research report on Friday, March 21st. UBS Group reiterated a “neutral” rating and set a $185.00 price objective (down previously from $250.00) on shares of Charles River Laboratories International in a research report on Friday, January 17th. Finally, JPMorgan Chase & Co. reduced their target price on shares of Charles River Laboratories International from $175.00 to $165.00 and set a “neutral” rating on the stock in a report on Thursday, February 20th. One investment analyst has rated the stock with a sell rating and sixteen have issued a hold rating to the stock. According to MarketBeat.com, Charles River Laboratories International presently has an average rating of “Hold” and a consensus target price of $182.00.

Insider Buying and Selling

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 4,400 shares of the firm’s stock in a transaction dated Thursday, February 20th. The stock was sold at an average price of $162.50, for a total value of $715,000.00. Following the transaction, the executive vice president now directly owns 20,013 shares of the company’s stock, valued at $3,252,112.50. This trade represents a 18.02 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, COO Birgit Girshick acquired 1,514 shares of Charles River Laboratories International stock in a transaction on Thursday, February 20th. The shares were bought at an average price of $164.63 per share, for a total transaction of $249,249.82. Following the purchase, the chief operating officer now owns 55,058 shares of the company’s stock, valued at $9,064,198.54. This represents a 2.83 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Corporate insiders own 1.30% of the company’s stock.

Charles River Laboratories International Stock Down 0.9 %

Shares of NYSE CRL opened at $114.71 on Friday. The stock has a market capitalization of $5.63 billion, a PE ratio of 764.73, a P/E/G ratio of 4.54 and a beta of 1.45. The company has a quick ratio of 1.14, a current ratio of 1.41 and a debt-to-equity ratio of 0.65. The firm has a fifty day moving average of $146.73 and a 200-day moving average of $171.12. Charles River Laboratories International, Inc. has a 52-week low of $91.86 and a 52-week high of $254.15.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.50 by $0.16. The firm had revenue of $1 billion during the quarter, compared to the consensus estimate of $983.63 million. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The firm’s quarterly revenue was down 1.1% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.46 earnings per share. On average, analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).